Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism

Journal of the American Society of Nephrology

Volumn 9, Issue 10, 1998, Pages 1948-1955

  Amuchastegui, Susana C ^b   Azzollini, Nadia ^b   Mister, Marilena ^b   Pezzotta, Angela ^b   Perico, Norberto ^a,b   Remuzzi, Giuseppe ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; LACIDIPINE; LOSARTAN;

ALLOGRAFT; ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; GRAFT SURVIVAL; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT; NEPHRON; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING;

EID: 0031718621     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Paul LC, Benediktsson H: Chronic transplant rejection: Magnitude of the problem and pathogenetic mechanisms. Transplant Rev 7: 96-113, 1993
2. Terasaki PI, Cecka JM, Cho Y, Cicciarelli J, Cohn M, Gjerston D, Lim E, Mickey MR, Ogura K, Park MS, Takemono S, Yuge J: Overview. In: Clinical Transplants, edited by Terasaki PI, Los Angeles, UCLA Tissue Typing Laboratory, 1990, pp 585-601
3. Opelz G, Schwartz V, Engelmann A, Back D, Wilk M, Keppel E: Long-term impact of HLA matching on kidney graft survival in cyclosporine-treated recipients. Transplant Proc 23: 373-375, 1991
4. Tilney NL, Whitley WD, Diamond JR, Kupiec-Weglinski JW, Adams DH: Chronic rejection: An undefined conundrum. Transplantation 52: 389, 1991
5. Tullius SG, Tilney NL: Both alloantigen-dependent and -independent factors influence chronic allograft failure. Transplantation 59: 313-318, 1995
6. Mackenzie HS, Brenner BM: Antigen-independent determinants of late renal allograft outcome: The role of renal mass. Curr Opin Nephrol Hypertens 5: 289-296, 1996
7. Brenner BM, Milford EL: Nephron underdosing: A programmed cause of chronic renal allograft failure. Am J Kidney Dis 21: 66-72, 1993
8. Brenner BM, Cohen RA, Milford EL: In renal transplantation, one size may not fit all. J Am Soc Nephrol 3: 162-169, 1992
9. Diamond JR, Tilney NL, Frye J, Ding G, McElroy J, Pesek-Diamond I, Yang H: Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection. Transplantation 54: 710-716, 1992
10. Mackenzie HS, Tullius SG, Heeman UW, Azuma H, Rennke HG, Brenner BM, Tilney NL: Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest 94: 2148-2152, 1994
11. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612-619, 1985
12. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930, 1986
13. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression: In proteinuric nephropathies, enhanced glomerular protein traffic contributes to interstitial inflammation and renal scarring. Kidney Int 51: 2-15, 1997
14. Luke RG: Pathophysiology and treatment of post transplant hypertension. J Am Soc Nephrol 2[Suppl 1]: S37-S44, 1991
15. Pfeffer JM, Pfeffer MA, Frohlich ED: Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. J Lab Clin Med 78: 957-962, 1971
16. Highashi A, Peters L: A rapid colorimetric method for the determination of inulin in plasma and urine. J Lab Clin Med 35: 475-480, 1950
17. Smith HW, Finkelsterin N, Aliminasa L, Crawford B: The renal clearance of substituted hippuric acid derivatives and other aromatic acid in dog and man. J Clin Invest 24: 388-404, 1945
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurements with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951
19. Wallenstein S, Zucker CL, Fleiss JL: Some statistical methods useful in circulation research. Circ Res 47: 1-9, 1980
20. Kingma I, Chea R, Davidoff A, Benediktsson H, Paul LC: Glomerular capillary pressures in long-surviving rat renal allografts. Transplantation 56: 53-60, 1993
21. Junaid A, Kren SM, Rosenberg ME, Nath KA, Hostetter TH: Physiological and structural responses to chronic experimental renal allograft injury. Am J Physiol 267: F1102-F1107, 1994
22. Benediktsson H, Chea R, Davidoff A, Paul LC: Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Transplantation 62: 1634-1642, 1996
23. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G: Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 85: 541-549, 1990
24. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, Bertani T, Remuzzi G: Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 4: 40-49, 1993
25. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90: 766-771, 1992
26. Paul LC, Benediktsson H: Post-transplant hypertension and chronic renal allograft failure. Kidney Int 48[Suppl 52]: S34-S37, 1995
27. Harris DCH, Hammond WS, Burke TJ, Schrier RW: Verapamil protects against progression of experimental chronic renal failure. Kidney Int 31: 41-46, 1987
28. Brunner FP, Thiel G, Hermle M, Bock HA, Mihatsh M: Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 36: 969-977, 1989
29. Dworkin LD, Levin RI, Benstein JA, Parker M, Ullian ME, Kim Y, Feiner HD: Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol 259: F598-F604, 1990
30. Dworkin LD, Feiner HD, Parker M, Tolbert E: Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 39: 1112-1117, 1991
31. Jackson B, Debrevi L, Cubela R, Whitty M, Johnston CI: Preservation of renal function in the rat remnant kidney model of chronic renal failure by blood pressure reduction. Clin Exp Pharmacol Physiol 13: 319-323, 1986
32. Podjarny E, Rathaus M, Shapira J, Kariv N, Pomeranz A, Zadok S, Bernheim J: Captopril, but not diltiazem, favorably affects the course of early chronic renal disease in rats. Nephron 55: 196-202, 1990
33. Jyothirmayi GN, Ramamurthi R, Reddi AS: Diltiazem prevents the progression of nephropathy in diabetic rats [Abstract]. J Am Soc Nephrol 1: 35, 1990
34. Jackson B, Debrevi L, Whitty M, Johnston CI: Progression of renal disease: Effects of different classes of antihypertensive therapy. J Hypertens 4[Suppl 5]: S269-S271, 1986
35. Anderson S, Rennke AG, Brenner BM: Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int 41: 891-897, 1992
36. Anderson S, Rennke HG, Garcia DL, Brenner BM: Short- and long-term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36: 526-536, 1989
37. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993-2000, 1986
38. Morelli E, Loon N, Meyer TW, Myers BD: Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 39: 76, 1990
39. Remuzzi A, Ruggenenti P, Mosconi L, Pata V, Viberti G, Remuzzi G: Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 6: 36, 1993
40. Ruggenenti P, Remuzzi G: The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes. Exp Nephrol 4[Suppl 1]: 53-60, 1996
41. Ruggenenti P, Remuzzi G: Angiotensin-converting-enzyme inhibitor therapy for non-diabetic progressive renal disease. Curr Opin Nephrol Hypertens 6: 489-495, 1997
42. Bell L, Madri JA: Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol 137: 7-12, 1990
43. Wolf G, Neilson EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 3: 1531-1540, 1993
44. Johnson RJ, Alpers CE, Yoshimura A: Renal injury from angiotensin II-mediated hypertension. Hypertension 19: 464-474, 1992
45. Chobanian AV, Haudenschild CC, Nickerson C, Drago R: Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 15: 327-331, 1990
46. Rolland PH, Charpiot P, Friggi A, Piquet P, Barlatier A, Scalbert E, Bodard H, Tranier P, Mercier C, Luccioni R, Garcon D: Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am J Cardiol 71: 22E-27E, 1993
47. Kobayashi J, Crawford SE, Backer CL, Zales VR, Takami H, Hsueh C, Huang L, Mavroudis C: Captopril reduces graft coronary artery disease in a rat heterotopic transplant model. Circulation 88[Part 2]: 286-290, 1993
48. Furukawa Y, Matsumori A, Hirozane T, Sasayama S: Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model: A comparative study with captopril. Circulation 93: 333-339, 1996
49. Curtis JJ: Hypertension following kidney transplantation. Am J Kidney Dis 23: 471-475, 1994
50. Epstein M: Calcium antagonists and the kidney: Future therapeutic perspectives. Am J Kidney Dis 21[Suppl 3]: 16-25, 1993
51. Textor SC, Schwartz L, Wilson DJ, Wiesner R, Romero JC, Augustine J, Kos P, Hay E, Gores G, Dickson ER: Systemic and renal effects of nifedipine in cyclosporine-associated hypertension. Hypertension 23[Suppl 1]: I220-I224, 1994
52. Rodicio JL, Morales JM, Alcazar JM, Ruilope LM: Calcium antagonists and renal protection. J Hypertens 1[Suppl 1]: S49-S53, 1993
53. Ruggenenti P, Perico N, Mosconi L, Gaspari F, Benigni A, Amuchastegui CS, Bruzzi I, Remuzzi G: Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 43: 706-711, 1993
54. Palmer BF, Dawidson I, Sagalowsky A, Sandor Z, Lu CY: Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 52: 640-645, 1991
55. Barenbrock M, Colmorgen U, Firschka E, Gellert J, Lippert J, Schroder K, Spieker C, Voigt-Ladner G, Wagner K, Neumayer HH, Rahn KH: A multicenter, randomized, double-blind, placebo-controlled, two-year trial to study the effect of nitrendipine on chronic renal transplant function. Clin Nephrol 43: 388-391, 1995
56. Kirk AJB, Omar I, Dark JH: Long-term improvement in renal function using nifedipine in cyclosporine-associated hypertension. Transplantation 50: 1061, 1990